Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: A systematic review

Heart

Volumn 100, Issue 23, 2014, Pages 1831-1836

  Niemeijer, Maartje N ^a   Van Den Berg, Marten E ^a   Eijgelsheim, Mark ^a   Van Herpen, Gerard ^a   Stricker, Bruno H ^a,b   Kors, Jan A ^a   Rijnbeek, Peter R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate of Health Care   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CARVEDILOL; CITALOPRAM; CLONIDINE; DIGOXIN; DOBUTAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; IBUTILIDE; ISOPRENALINE; MAGNESIUM SULFATE; METOPROLOL; NORTRIPTYLINE; PAROXETINE; PEMOLINE; SERTRALINE; SEVOFLURANE; SILDENAFIL; SOTALOL; VENLAFAXINE; YOHIMBINE;

BAZETT FORMULA; CARDIOVASCULAR MORTALITY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HUMAN; MATHEMATICAL PARAMETERS; MEDICAL RESEARCH; ONLINE ANALYSIS; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLICATION; QT PROLONGATION; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; SHORT QT INTERVAL; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW; ARRHYTHMIAS, CARDIAC; COMPLICATION; DEATH, SUDDEN, CARDIAC; HEART RATE; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; TIME;

ARRHYTHMIAS, CARDIAC; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84922393923     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-305671     Document Type: Review

References (30)

1. Straus SM, Bleumink GS, Dieleman JP, et al. The incidence of sudden cardiac death in the general population. J Clin Epidemiol 2004;57:98-102.
2. Chugh SS, Reinier K, Teodorescu C, et al. Epidemiology of sudden cardiac death: clinical and research implications. Prog Cardiovasc Dis 2008;51:213-28.
3. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol 2007;22:39-43.
4. Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002;112:58-66.
5. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
6. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation 1998;98:2334-51.
7. Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovasc Electrophysiol 2001;12:369-81.
8. European Medicines Agency. ICH Topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs. 2005.
9. Food and Drug Administration. International conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 2005;70:61134-5.
10. van Opstal JM, Schoenmakers M, Verduyn SC, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001;104:2722-7.
11. Thomsen MB, Matz J, Volders PG, et al. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 2006;112:150-70.
12. Shah RR. Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol 2002;16:119-24.
13. Carlsson L, Andersson B, Linhardt G, et al. Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo. J Cardiovasc Pharmacol 2009;54:82-9.
14. Flore V, Claus P, Antoons G, et al. Microvolt T-wave alternans and beat-to-beat variability of repolarization during early postischemic remodeling in a pig heart. Heart Rhythm 2011;8:1050-7.
15. Gallacher DJ, Van de Water A, van der Linde H, et al. In vivo mechanisms precipitating torsades de pointes in a canine model of drug-induced long-QT1 syndrome. Cardiovasc Res 2007;76:247-56.
16. Jacobson I, Carlsson L, Duker G. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit. J Pharmacol Toxicol Methods 2011;63:40-6.
17. Lengyel C, Varro A, Tabori K, et al. Combined pharmacological block of IKr and IKs increases short-term QT interval variability and provokes torsades de pointes. Br J Pharmacol 2007;151:941-51.
18. Panyasing Y, Kijtawornrat A, del Rio C, et al. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes. J Pharmacol Toxicol Methods 2010;62:148-56.
19. Takahara A, Nakamura Y, Sugiyama A. Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multi ion channel-blockers bepridil and amiodarone. Eur J Pharmacol 2008;596:127-31.
20. Takahara A, Sugiyama A, Ishida Y, et al. Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias. Br J Pharmacol 2006;147:634-41.
21. Vincze D, Farkas AS, Rudas L, et al. Relevance of anaesthesia for dofetilide-induced torsades de pointes in (alpha)1-adrenoceptor-stimulated rabbits. Br J Pharmacol 2008;153:75-89.
22. Roden DM. Mechanisms and management of proarrhythmia. Am J Cardiol 1998;82:49I-57I.
23. Thomsen MB, Verduyn SC, Stengl M, et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004;110:2453-9.
24. Berger RD, Kasper EK, Baughman KL, et al. Beat-to-beat QT interval variability: novel evidence for repolarization lability in ischemic and nonischemic dilated cardiomyopathy. Circulation 1997;96:1557-65.
25. Roden DM. Taking the "Idio" out of "Idiosyncratic": predicting Torsades de Pointes. Pacing Clin Electrophysiol 1998;5:1029-34.
26. Tereshchenko LG, Berger RD. Towards a better understanding of QT interval variability. Therapeutic Advances in Drug Safety 2011;6:245-51.
27. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
28. Yeragani VK, Tancer ME, Glitz D, et al. Significant difference in beat-to-beat QT interval variability among different leads. Heart Disease 2002;4:344-8.
29. Baumert M, Starc V, Porta A. Conventional QT variability measurement vs. template matching techniques: Comparison of performance using simulated and real ECG. PLoS ONE 2012;7.
30. Oosterhoff P, Tereshchenko LG, van der Heyden MA, et al. Short-term variability of repolarization predicts ventricular tachycardia and sudden cardiac death in patients with structural heart disease: a comparison with QT variability index. Heart Rhythm 2011;8:1584-90.